Related Experiment Video
Updated: Jul 19, 2026
08:47
Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
Published on: April 21, 2022
Mucin overproduction in chronic inflammatory lung disease
Hans-Peter Hauber1, Susan C Foley, Qutayba Hamid
1McGill University, Montreal, Quebec.
Canadian Respiratory Journal
|September 20, 2006
Summary
Chronic lung diseases involve mucus overproduction. This review examines how mediators like neutrophil elastase and cytokines upregulate mucins, the key components of mucus, in secreted mucin production.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Biochemistry
Background:
- Mucus hypersecretion is a hallmark of chronic inflammatory lung diseases.
- Mucins are essential gel-forming glycoproteins that contribute to mucus properties.
- Various mediators can stimulate mucin production.
Purpose of the Study:
- To review the mechanisms underlying the upregulation of secreted mucins.
- To discuss the role of specific mediators in mucin induction.
Main Methods:
- Literature review of mechanisms controlling mucin secretion.
- Analysis of signaling pathways involved in mucin gene expression and secretion.
Main Results:
- Mucin production is upregulated by diverse stimuli including neutrophil elastase, bacterial products, cytokines, growth factors, and cigarette smoke.
- Cystic fibrosis transmembrane conductance regulator (CFTR) malfunction is implicated in aberrant mucin secretion.
Conclusions:
- Understanding these upregulation mechanisms is crucial for developing targeted therapies for mucus-related lung pathologies.
- Identifying key mediators provides insights into disease pathogenesis and potential therapeutic targets.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...